CLAPPS: Pre-incision Versus Post-incision Local Anesthetic During Robotic Sacrocolpopexy

Sponsor
Northwell Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT04996251
Collaborator
(none)
128
3
2
23
42.7
1.9

Study Details

Study Description

Brief Summary

Obtaining Likest-pain scale score on postoperative day one after injection of local anesthetic into incision sites of a laparoscopic/robotic-assisted sacrocolpopexy

Condition or Disease Intervention/Treatment Phase
  • Drug: Bupivacaine Injection
Phase 4

Detailed Description

Pelvic organ prolapse is becoming more common as women's life expectancy is increasing and the prevalence of obesity is rising. Many women undergo pelvic reconstructive surgery to treat their prolapse and improve their quality of life. The incidence of pelvic organ prolapse is 1.5-1.8 surgeries per 1,000 women years. Approximately 300,000 pelvic reconstructive surgeries are performed each year in the United States. There is a wide variety in surgical approaches and procedures for prolapse. One such procedure is a sacrocolpopexy in which the cervix or vaginal cuff is lifted to the anterior longitudinal ligament overlying the sacrum via a mesh graft. This can be done in a minimally invasive fashion with a laparoscopic or robotic approach or in an open abdominal approach. Numerous studies have shown this procedure to have a high success rate and long-term durability. As robotic/laparoscopic approach to surgery has shown shorter hospital-stays and improved patient outcomes, the robotic-assisted sacrocolpopexy has been rapidly incorporated into clinical practice.

In general, surgery causes a release of painful chemical mediators which has led to increased narcotic use, increased narcotic addiction, and number of pills prescribed. Most individuals who undergo surgery will require narcotics postoperatively to control their pain and some individuals have to extend their hospital stay until adequate pain control is achieved. Our study is aimed to reduce narcotic use, decrease hospital stay due to pain issues and determine if timing of adjunct pain medication improves pain scales for patients.

As postoperative pain after minimally invasive surgery is complex, specialists suggest that the effective analgesic treatment should be a multimodal approach. Use of local anesthetic with bupivacaine at robotic/laparoscopic trocar sites is the standard of care, however, there is no standard as to optimal timing that is most beneficial for patients to decrease pain. Currently, bupivacaine is used by providers at the trocar sites at either the beginning of the case or at the end of the case. From clinical observation, it appears that postoperative pain levels reported from patients receiving either at the beginning of surgery (pre-) or end (post-incision) of the surgery are similar. This study aims to examine the difference in postoperative day one pain levels reported by patients between the two infiltration methods

Study Design

Study Type:
Interventional
Anticipated Enrollment :
128 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Clinical Effectiveness of Pre-incision Versus Post-incision Local Anesthetic During Laparoscopic/Robotic Sacrocolpopexy
Actual Study Start Date :
Jul 30, 2021
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: subcutaneous infiltration pre-incision

Marcaine (bupivacaine) injected in the umbilical port site subcutaneously, while in the other 4 sites injection under direct visualization

Drug: Bupivacaine Injection
0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
Other Names:
  • Marcaine
  • Experimental: subcutaneous infiltration post-incision

    local anesthetic infiltrated subcutaneously at the end of the procedure after trocar removal and after skin closure with suture

    Drug: Bupivacaine Injection
    0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
    Other Names:
  • Marcaine
  • Outcome Measures

    Primary Outcome Measures

    1. Likert-pain scale score on postoperative day one [18-24 hours]

      Difference in Likert-pain scale score difference between pre-incision versus post-incision subcutaneous infiltration with 4-5 milliliters 0.25% Bupivacaine (0 is no pain; 10 is worst pain imaginable)

    Secondary Outcome Measures

    1. Narcotic Usage [2 weeks]

      Compare narcotic usage (pills used) until first postoperative appointment

    2. Brief Pain Inventory [2 weeks]

      Compare brief pain inventory questionnaire survey responses at first postoperative visit

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Females 18+ years old who are undergoing robotic/laparoscopic assisted sacrocolpopexy

    • With/without hysterectomy

    • With/without unilateral/bilateral salpingectomy

    • With/without unilateral/bilateral oophorectomy

    • With/without mid-urethral sling

    • With/without anterior/posterior vaginal repair

    • English or Spanish speaking

    • Weight ≥ 120 lb

    Exclusion Criteria:
    • Females < 18 years old

    • Chronic pelvic pain/chronic pain syndromes

    • Fibromyalgia

    • Pregnant or breastfeeding patients

    • Concomitant procedure for hernia repair or rectal prolapse repair

    • Undergoing primary vaginal prolapse surgery

    • Contraindications to taking the following medications: Bupivacaine

    • Patients who weight is < 120lb

    • Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation

    • Pudendal or spinal nerve block given during surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 South Shore University Hospital Bay Shore New York United States 11706
    2 Huntington Hospital Huntington New York United States 11743
    3 North Shore University Hospital Manhasset New York United States 11030

    Sponsors and Collaborators

    • Northwell Health

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Harvey Winkler, System Chief of Urogynecology Division; Principal Investigator, Northwell Health
    ClinicalTrials.gov Identifier:
    NCT04996251
    Other Study ID Numbers:
    • 21-0422
    First Posted:
    Aug 9, 2021
    Last Update Posted:
    Aug 17, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 17, 2021